Skip to main content

Upcoming holiday closures 

Quest Patient Service Centers will be closed on Friday, July 3 and Saturday, July 4, 2026, in observance of Independence Day, and to give our frontline team the time to recharge. Don't let the holiday interrupt your care. Plan your visit today.

Hide
Quest Diagnostics

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology

Authors: Weber DM, Stroh MA, Taylor SW, Lagier RJ, Louie JZ, Clarke NJ, Vaillancourt DE, Rayaprolu S, Duara R, Racke MK

Citation: Neurol Clin Pract. 2025;15:e200546. doi:10.1212/CPJ.0000000000200546

Specialties: Neurology

Download key summary

Related content

On-Demand Webinar
Biomarker Testing in Alzheimer’s Disease
Publication
EXPRESS: New Plasma LC-MS/MS Assays for the Quantitation of Beta-amyloid Peptides and Identification of Apolipoprotein E Proteoforms for Alzheimer’s Disease Risk Assessment
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
Conference Presentation
Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.